- Home
- SVRA vs VOR Comparison
SVRA vs VOR Comparison
Compare SVRA & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRA | VOR |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SVRA | VOR |
|---|---|---|
| Price | $5.51 | $19.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $7.33 | ★ $45.33 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $430.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.43 | $1.62 |
| 52 Week High | $7.01 | $49.95 |
Technical Indicators
Market Signals| Indicator | SVRA | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 56.67 |
| Support Level | $5.32 | $11.62 |
| Resistance Level | $6.15 | $19.70 |
| Average True Range (ATR) | 0.30 | 1.49 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 9.72 | 55.84 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.